preclinical research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-25. Numbers and descriptions here follow the published literature rather than marketing material.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
The company was founded by Herbert Hyman (1931–2014) in September 1963, as a coffee service for offices. His wife Mona (whom he married in 1966) and he honeymooned in Sweden where they discovered quality coffee. This sparked the decision to import, roast and sell gourmet coffee in Los Angeles, opening the first Coffee Bean store in 1968 in the Los Angeles neighborhood of Brentwood. Innovations included selling whole beans and touting their country of origin and allowing customers to observe the beans being roasted and then to sample varieties before making a purchase. By the 1970s the firm had expanded to 10 stores in Southern California and had added exotic teas to the menu. In the summer of 1987 an employee brought a blender to a Westwood store where he mixed together ice, coffee extract and chocolate powder, paving the way for the company's signature Ice Blended drinks. With the invention of the Ice Blended, the chain saw a surge in popularity. The drink was a predecessor to the Starbucks Frappuccino. In 1991, when it was first planning to expand into Los Angeles, Starbucks tried to purchase the firm, but Hyman turned them down. The opening of Starbucks stores in Los Angeles unexpectedly helped Coffee Bean's business, by driving curious customers to the area. In 1996, the Hymans sold the Asian franchise rights to Singaporean brothers Victor Sassoon and Sunny Sassoon. The Sassoons quickly expanded the company in the US and internationally, opening the first outlet in Singapore in 1996, and in Malaysia the following year.
Allergic diseases are caused by inappropriate immunological responses to harmless antigens driven by a TH2-mediated immune response. Many bacteria and viruses elicit a TH1-mediated immune response, which down-regulates TH2 responses. The first proposed mechanism of action of the hygiene hypothesis was that insufficient stimulation of the TH1 arm of the immune system leads to an overactive TH2 arm, which in turn leads to allergic disease. In other words, individuals living in too sterile an environment are not exposed to enough pathogens to keep the immune system busy. Since our bodies evolved to deal with a certain level of such pathogens, when they are not exposed to this level, the immune system will attack harmless antigens. Thus, normally benign microbial objects—like pollen—will trigger an immune response. The hygiene hypothesis was developed to explain the observation that hay fever and eczema, both allergic diseases, were less common in children from larger families, which were, it is presumed, exposed to more infectious agents through their siblings, than in children from families with only one child. It is used to explain the increase in allergic diseases that have been seen since industrialization, and the higher incidence of allergic diseases in more developed countries. The hygiene hypothesis has now expanded to include exposure to symbiotic bacteria and parasites as important modulators of immune system development, along with infectious agents. Epidemiological data support the hygiene hypothesis.
123I is produced by proton irradiation of 124Xe. The caesium isotope produced is unstable and decays to 123I. The isotope is usually supplied as the iodide and hypoiodate in dilute sodium hydroxide solution, at high isotopic purity. 123I has also been produced at Oak Ridge National Laboratories by proton bombardment of 123Te. 123I decays by electron capture with a half-life of 13.22 hours. The emitted 159 keV gamma ray is used in single-photon emission computed tomography (SPECT). A 127 keV gamma ray is also emitted. 125I is frequently used in radioimmunoassays because of its relatively long half-life (59 days) and ability to be detected with high sensitivity by gamma counters. 129I is present in the environment as a result of the testing of nuclear weapons in the atmosphere. It was also produced in the Chernobyl and Fukushima disasters. 129I decays with a half-life of 15.7 million years, with low-energy beta and gamma emissions. It is not used as a tracer, though its presence in living organisms, including human beings, can be characterized by measurement of the gamma rays.
== Clinical significance == A missense mutation at 17q25 in the GCGR gene is associated with diabetes mellitus type 2. Inactivating mutation of glucagon receptor in humans causes resistance to glucagon and is associated with pancreatic alpha cell hyperplasia, nesidioblastosis, hyperglucagonemia, and pancreatic neuroendocrine tumors, also known as Mahvash disease.
Raymond’s “micro-mosaics” evoked pointillism and the yet-to-come pixellation. Raymond worked with a plank of wood on his lap, a magnifying glass in one hand and a paintbrush or a dip pen in the other. He would cut the tip of the nib so he could reproduce the tesserae perfectly.
Sources: en.wikipedia.org
==== Autonomous republics ==== All sixteen republics under the Russian SFSR Crimean ASSR under Ukraine Karakalpak ASSR under Uzbekistan Abkhaz SSR (former ASSR under Georgia, which had declared independence)
== In popular culture == In Jules Verne's 1870 novel, 20,000 Leagues Under The Sea, the story is written in the form of narration from journal entries by Professor Pierre Aronnax, a naturalist from the Paris Museum of Natural History (the name of the museum at the time). The Gallery of Palaeontology and Comparative Anatomy and other parts of Jardin des Plantes was a source of inspiration for French graphic novelist Jacques Tardi. The gallery appears on the first page and several subsequent pages of Adèle et la bête (Adèle and the Beast; 1976), the first album in the series of Les Aventures extraordinaires d'Adèle Blanc-Sec. The story opens with a 136-million-year-old pterodactyl egg hatching, and a live pterodactyl escaping through the gallery glass roof, wreaking havoc and killing people in Paris. The Gallery of Palaeontology and Comparative Anatomy returned the favour by placing a life size cardboard cutout of Adèle and the hatching pterodactyl in a glass cabinet outside the main entrance on the top floor balcony. The Pulitzer Prize–winning novel All the Light We Cannot See, by Anthony Doerr, partially takes place at the MNHN; the father of the protagonist Marie-Laure works as the chief locksmith of the museum. The story also makes many references to Jules Verne's novel 20,000 Leagues Under the Seas, and the fictional naturalist and narrator Professor Pierre Aronnax. Marie-Laure was gifted braille books of the novel by her father.
Anti-citrullinated protein antibodies (ACPAs) are autoantibodies (antibodies to an individual's own proteins) that are directed against peptides and proteins that are citrullinated. They are present in the majority of patients with rheumatoid arthritis. Clinically, cyclic citrullinated peptides (CCP) are frequently used to detect these antibodies in patient serum or plasma (then referred to as anti–citrullinated peptide antibodies). During inflammation, arginine amino acid residues can be enzymatically converted into citrulline residues in proteins such as vimentin, by a process called citrullination. If their shapes are significantly altered, the proteins may be seen as antigens by the immune system, thereby generating an immune response. ACPAs have proved to be powerful biomarkers that allow the diagnosis of rheumatoid arthritis (RA) to be made at a very early stage. In July 2010, the 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria were introduced. These new classification criteria include ACPA testing, and overruled the "old" ACR criteria of 1987 and are adapted for early RA diagnosis.
Profilin was first described by Lars Carlsson in the lab of Uno Lindberg and co-workers in the early 1970s as the first actin monomer binding protein. It followed the realization that not only muscle, but also non-muscle cells, contained high concentrations of actin, albeit in part in an unpolymerized form. Profilin was then believed to sequester actin monomers (keep them in a pro-filamentous form), and release them upon a signal to make them accessible for fast actin polymer growth.
Silver sulfadiazine (SSD) is a topical antibiotic used in partial thickness and full thickness burns to prevent infection. It was discovered in the 1960s, and was the standard topical antimicrobial for burn wounds for decades. However systemic reviews in 2014, 2017 and 2018 concluded that more modern treatments, both with and without silver, show better results for wound healing and infection-prevention than silver sulfadiazine, and therefore SSD is no longer generally recommended. It is on the World Health Organization's List of Essential Medicines. The US Food and Drug Administration (FDA) approved a number of topical preparations of silver sulfadiazine for treatment of second-degree and third-degree burns.
Sources: en.wikipedia.org
== External links == NLM Hazardous Substances Databank – Plutonium, Radioactive Table of nuclides with 239Pu data at Kaye and Laby Online Half-life of Plutonium-239 Archived 2011-08-15 at the Wayback Machine
As a result, the more interesting possibilities remain on the table and the mystery of the tension deepens." Research suggests that replacing half of the beef, chicken, dairy and pork products consumed globally with plant-based alternatives by 2050 could reduce the amount of land used by agriculture by almost a third, bring deforestation for agriculture nearly to a halt, help restore biodiversity through rewilding the land and reduce GHG emissions from agriculture by 31%, paving a clearer path to reaching climate and biodiversity targets. A separate study (6 Sep) using a global food system model suggests that net-negative greenhouse gas emissions could be possible in a sustainable food system achievable with full global deployment of diverse interventions, with the most promising options including hydrogen-powered fertilizer production, livestock feeds, organic and inorganic soil amendments, agroforestry, sustainable seafood harvesting practices, and adoption of flexitarian diets. 18 September A new palm oil substitute called PALM-ALT is presented by researchers. The plant-based ingredient is shown to be 70% better for the environment than conventional palm oil and is described as "the holy grail to replace it". The Linac Coherent Light Source at the SLAC National Accelerator Laboratory is upgraded to LCLS-II and successfully demonstrates its first X-rays, which are fired 8,000 times faster and are 10,000 times brighter than the previous version.
====== Order Proboscidea ====== Family Elephantidae (Elephants) Elephas maximus, Asian elephant, (2015, 2024) † Mammuthus primigenius, Wooly mammoth, (2015) Loxodonta africana, African bush elephant, (2009, 2024) Loxodonta cyclotis, African forest elephant, (2018)
In April 2021 Noakes pleaded guilty in France to manufacturing and selling fake medicinal products and cosmetics by Internet and sentenced to 4 years of jail. A 2019 Business Insider report detailed the activities of Amanda Mary Jewell, who sold GcMAF for years as an unlicensed cure for several medical conditions, including cancer and autism. Jewell is not a medical doctor.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.